Esperion Therapeutics
ESPR
ESPR
156 hedge funds and large institutions have $1.21B invested in Esperion Therapeutics in 2018 Q2 according to their latest regulatory filings, with 22 funds opening new positions, 67 increasing their positions, 45 reducing their positions, and 52 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more ownership
Funds ownership: →
less funds holding
Funds holding: →
less capital invested
Capital invested by funds: $ → $
43% less funds holding in top 10
Funds holding in top 10: 7 → 4 (-3)
58% less first-time investments, than exits
New positions opened: 22 | Existing positions closed: 52
76% less call options, than puts
Call options by funds: $25M | Put options by funds: $105M
Holders
156
Holding in Top 10
4
Calls
$25M
Puts
$105M
Top Buyers
| 1 | +$52.1M | |
| 2 | +$40.5M | |
| 3 | +$33.7M | |
| 4 |
BB
BB Biotech
Schaffhausen,
Switzerland
|
+$30.2M |
| 5 |
BC
Boxer Capital
San Diego,
California
|
+$18.6M |
Top Sellers
| 1 | -$31.4M | |
| 2 | -$18.4M | |
| 3 | -$18.1M | |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$17.3M |
| 5 |
PA
Pinnacle Associates
New York
|
-$16M |